Invivyd (NASDAQ:IVVD - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $34.45 million for the quarter.
Invivyd (NASDAQ:IVVD - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.10. The firm had revenue of $13.80 million for the quarter, compared to analysts' expectations of $13.57 million. On average, analysts expect Invivyd to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Invivyd Trading Down 1.1 %
Invivyd stock traded down $0.01 on Tuesday, hitting $0.57. 110,289 shares of the stock traded hands, compared to its average volume of 4,274,882. Invivyd has a 1 year low of $0.35 and a 1 year high of $2.74. The firm has a market cap of $68.26 million, a P/E ratio of -0.29 and a beta of 0.40. The business's fifty day simple moving average is $0.69 and its 200 day simple moving average is $0.77.
Wall Street Analysts Forecast Growth
IVVD has been the topic of a number of analyst reports. D. Boral Capital reissued a "buy" rating and issued a $9.00 price target on shares of Invivyd in a research report on Thursday, March 20th. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Invivyd in a report on Wednesday, March 26th.
Read Our Latest Report on IVVD
About Invivyd
(
Get Free Report)
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
See Also

Before you consider Invivyd, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.
While Invivyd currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.